الفهرس 
Introduction & Aim of The WorkOnly 14 pages are availabe for public view
 |  | from | 244 |  |  |
| | | from | 244 | | |
Abstract
Stroke is a leading cause of adult disability and mortality. Type II DM is a major risk factor for ischemic stroke accompanied by vascular dysfunction and poor cerebrovascular outcome. Lixisenatide is a GLP-1 analogue that is recently used for DM treatment with established neuroprotective properties.
In this concern we designed three experimental designs to investigate the ameliorative effect of lixisenatide in global I/R rat model and elaborate the underline mechanisms that could mediate the proposed activity. Moreover, the current study investigated and compared the neuroprotective effect of lixisenatide against glimepiride on diabetic rats subjected to global I/Rinjury.
This study demonstrated that lixisenatide ameliorated I/R-induced injury. Lixisenatide post treatment could diminish neurological damage and alleviates neurobehavioral dysfunction in I/R-injured rats. Lixisenatide may enhance angiogenesis and promote neuronal survival through anti-oxidative, anti-inflammatory and anti-apoptotic actions that mediated dependently/independently via GLP-1R activation.